NASDAQ:PHAS - PhaseBio Pharmaceuticals Price Target & Analyst Ratings

$4.75
-0.26 (-5.19 %)
(As of 09/17/2019 04:00 PM ET)
Today's Range
$4.5570
Now: $4.75
$5.02
50-Day Range
$4.71
MA: $7.23
$9.19
52-Week Range
$2.55
Now: $4.75
$16.65
Volume259,687 shs
Average Volume262,727 shs
Market Capitalization$136.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Analyst Ratings

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for PhaseBio Pharmaceuticals in the last 12 months. Their average twelve-month price target is $20.6667, suggesting that the stock has a possible upside of 335.09%. The high price target for PHAS is $27.00 and the low price target for PHAS is $17.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $20.6667$19.6667$19.6667$16.6667
Price Target Upside: 335.09% upside86.95% upside86.95% upside251.62% upside

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Consensus Price Target History

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/11/2019William BlairReiterated RatingOutperformHigh
9/9/2019Stifel NicolausLower Price TargetBuy$20.00 ➝ $17.00Medium
5/24/2019CitigroupSet Price TargetBuy$27.00High
11/13/2018Needham & Company LLCInitiated CoverageBuy ➝ Buy$18.00High
11/12/2018CowenInitiated CoverageOutperformHigh
(Data available from 9/17/2017 forward)
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel